CombinatoRx, Incorporated (NASDAQ: CRXX) is seeing its stock implode this morning. The company released data from its Phase IIb study of Synavive (CRx-102) for knee osteoarthritis showing that its Synavive test was not statistically…
The list of management screw-ups at Boston Scientific (BSX) is almost too long to number. It bought rival Guidant and added $7 billion in debt in the process. Some of Guidant’s products were not…
UBS has decided to downgrades the hospital sector this morning. It seems that perhaps not all medical and healthcare stocks are immune from a rapidly weakening economy. We have seen downgrades on three of…
Cardinal Health, Inc. (NYSE: CAH) is going to shuffle things up. The healthcare products and services company plans a tax-free spin-off of its clinical and medical products businesses as a separate public company. The…
It appears that the IPO market has lost another IPO. Fluidigm Corp. was set to come public. We had it on the docket last week, then this week. Now it appears to be postponed…
This might not be the biggest of biotech mergers out there, but deals are continuing in the bio-space. Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) has entered into a definitive merger agreement to acquire Pharmacopeia (NASDAQ:…
ImClone Systems Inc. (NASDAQ: IMCL) is among the biotech bonanza merger candidates with one deal on the table and perhaps an unofficial deal waiting in the wings. Bristol-Myers Squibb Co. (NYSE: BMY) has now…
Gilead Sciences Inc. (NASDAQ: GILD) is trading down this morning. Goldman Sachs maintained its buy rating on the stock, but took down its price target to $58 from $59. This report is after a…
The stent business in the US has been dying and it is in trouble overseas. Stents are small mesh tubs which keep clogged arteries open. Last year, several studies showed that stents could cause…
There is some very hopeful data out there this morning on cancer survival. Bristol-Myers Squibb Co. (NYSE: BMY) and Medarex, Inc. (NASDAQ: MEDX) have released updated survival data from three Phase II studies of…
Bristol-Myers Squibb (NYSE: BMY) has sent a letter to Imclone Systems (NASDAQ: IMCL) in response to yesterday’s rejection of its buyout offer. It said it is disappointed that the $60.00 bid was passed up…
ImClone Systems Inc. (NASDAQ: IMCL) is a biotech buyout bonanza stock that traders and investors have been watching closely. The company has said that the proposed $60.00 per share cash buyout from Bristol-Myers Squibb…
A usually quiet Cardica, Inc. (NASDAQ: CRDC) is seeing a huge move in its stock today on strong upside volume. The company has won FDA marketing approval to sell its PAS-Port Proximal Anastomosis System…
If you just read headlines on Biodel Inc. (Nasdaq: BIOD) this morning, you would have thought the news coming out of the company was either good or just neutral. Today was the exact opposite,…
Merck (MRK) and Schering-Plough (SGP) make two of the most widely sold drugs in the world. One is cholesterol drug Zetia. Another is a related drug called Vytorin. The sales of the treatments topped…